News

The findings may open up new treatment avenues for patients suffering from inflammatory disorders and depression. Because an overactive inflammatory response may contribute to a number of medical

The new offer from Actavis is worth 795 kuna per share compared with the 743 kuna per share offer currently on the table from US-based Barr. Before the

Results were consistent with previously reported data, showing immune responses when the vaccine was used alone or in combination with a DNA primer vaccine. In a study of

The vaccine was well-tolerated and the subjects showed strong cell immunity responses that may be important for controlling HIV infection. The trial involved priming an immune response with

The agreement will allow Akorn to manufacture injectable products in finished dosage form for GeneraMedix, who will market these products under the GeneraMedix label. The agreement includes products

Under the extension, ImmunoGen will no longer be obligated to present new targets for antibody-based anticancer therapeutics to Sanofi-Aventis, enabling the company to use such targets in the

Ablvax is a therapeutic vaccine currently being evaluated as a treatment for patients with resistant chronic myeloid leukemia (CML). Under terms of the agreement, MolecularMD will perform molecular

A Norwegian court ruled in Ranbaxy’s favor in a case involving two patents on Lipitor in Norway. However, as Pfizer points out, Ranbaxy is still unable to produce

Fluoxetine capsules are indicated for the treatment of premenstrual dysphoric disorder (PMDD). The disorder causes severe depression, bad mood swings and tension before menstruation. Eli Lilly’s Sarafem pulvules